Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | HRH2 | P25021 | 4/20 | 0.37 |
| ▸ | HRH1 | P35367 | 4/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | LOX | P28300 | 1/20 | 0.34 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095700 | 0.90 | HRH3 (0.42) | CYP19A1HRH2HRH1HRH3HTR7 | |
| SCHEMBL2963106 | 0.87 | KCNH2 (0.41) | CYP19A1HRH2HRH1HRH3HTR7 | |
| SCHEMBL6996965 | 0.87 | SIGMAR1 (0.41) | CYP19A1HRH2HRH1HRH3HTR7 | |
| SCHEMBL5965627 | 0.85 | HRH2 (0.37) | CYP19A1HRH2HRH1HRH3HTR7 | |
| SCHEMBL7035035 | 0.84 | MEN1 (0.39) | HRH2HRH1HRH3GRIA2KCNH2 | |
| SCHEMBL6989155 | 0.84 | HRH3 (0.48) | HRH2HRH1HRH3 | |
| SCHEMBL7033710 | 0.83 | HRH2 (0.38) | CYP19A1HRH2HRH1HRH3HTR7 | |
| SCHEMBL7033675 | 0.82 | HRH2 (0.37) | CYP19A1HRH2HRH1ALDH1A1CYP3A4 | |
| SCHEMBL6990862 | 0.82 | THRB (0.43) | HRH2HRH1HRH3HTR7CYP2C9 | |
| SCHEMBL6997428 | 0.81 | DRD2 (0.41) | HRH2HRH1HTR7HTR6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | KCNH1, LBR, CACNA1E | CYP19A1 1629/4885HRH2 229/4885HRH1 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.